Sun Pharmaceutical receives warning letter from USFDA for Halol facility

The Halol facility was placed under Import Alert by USFDA.

CPhI & P-MEC India expo to encourage cost-effective solutions in India’s march towards a Rs 10.5 lakh crore pharma market by 2030

The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees

Sun Pharmaceutical gets OAI from USFDA for Mohali facility

10th Merck Bioforum India 2022 on Sept. 6-8

This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape

Sun Pharma gets OAI from USFDA for Halol facility

The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved

Sun Pharma Chairman Israel Makov to retire on completion of term

He was appointed a Board member and the Chairman in 2012.

Sun Pharma and Cosmo announce territory expansion of license and supply agreements for WINLEVI

Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.

Sun gets 10 observations from USFDA for Halol facility

The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days

Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.

Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021

Fifty-five manufacturers selected for Pharma PLI sector

The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme